EV/EBITDA Multiple: Synlogic Inc. (SYBX)

Corporate company logo of synlogictx.com (SYBX)

Synlogic, Inc. (SYBX) focuses on creating synthetic biologics, meaning its financial stability is tied to the effectiveness of its scientific research. The market dynamics of the asset with the 0.00 indicator highlight the specifics of the non-cyclical sector, where the demand for congenital pathology therapies remains stable regardless of market fluctuations. However, competitive advantages are currently diluted due to the suspension of primary programs, and activities are limited solely to the preservation of existing capital.

SYBX (Synlogic) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 01/24/2026

synlogictx.com (SYBX) - metric breakdowns and financial figures

- market price and analyst price targets:
Price Chart Synlogic|SYBX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Synlogic, Inc.|SYBX - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Synlogic|SYBX - Total Net Assets|Market Capitalization to Book Value Ratio synlogictx.com|SYBX - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Synlogic, Inc.|SYBX - Long-Term Debt to Equity|Short-Term Debt to Equity Synlogic|SYBX - Company Cumulative Debt|Debt to Book Capitalization Ratio Synlogic, Inc.|SYBX - Company Long-Term Debt|Company Short-Term Debts Synlogic|Quick Liquidity synlogictx.com
- net income and valuation multiples indicators:
SYBX - Net Financial Result|Expected Profit Synlogic, Inc.|SYBX - Price to Earnings Ratio|Future Price to Earnings Synlogic|SYBX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Synlogic, Inc.|SYBX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Synlogic|SYBX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months synlogictx.com|SYBX - Earnings per share growth in current year|Net earnings per share growth forecast for next year Synlogic, Inc.
Initial company analysis:SYBX (Synlogic Corp)
Product sample of Synlogic

To assess long-term risks, the investor utilizes the ratio of total enterprise value (market capitalization and debt) to operating profit, which allows for the real-time tracking of asset revaluations via EV/EBITDA dynamics. In the case of Synlogic, Inc. (SYBX), this indicator reflects not investment attractiveness, but rather the stagnation of a company whose operations are limited solely to maintaining cash balances following the abandonment of its primary developments.

Who Synlogic, Inc. competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascendis Pharma Inc. ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA rhythmtx.com|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Corp|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (soleno.life)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Amicus Therapeutics, Inc. FOLD|89bio Inc (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Pharmaceuticals, Inc.|MBX Biosciences, Inc. (MBX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Altimmune Corp (ALT)|Enterprise Value to EBITDA Ratio Aardvark Pharma AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences SGMT|Total Company Value to Operating Income Before Depreciation Ratio bioagelabs.com (BIOA)|BMEA: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Quince Therapeutics|Fractyl (GUTS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation VTVT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agape ATP Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PLUR|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lipocine (LPCN)|MTNB - Company Value to EBITDA|EV/EBITDA Multiple SPRB (Spruce Biosciences)|Enterprise Value to EBITDA Multiple Galecto Corporation|Carmell Corporation - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio lumos-pharma.com LUMO|ONVO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Radius Recycling Inc.